BASKING RIDGE, N.J., March 12 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals, Inc. , a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, will be presenting at the 6th Annual Sachs Associates North America Forum for Investing and Partnering in Biotech on Monday, March 12th at 11:40 AM (EST). The event, which will be held at The Fairmont Copley Plaza, is expected to draw over 500 delegates from the USA and overseas representing both listed and private biotech companies.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )
Daniel Greenleaf, president and CEO of VioQuest, will provide an overview of the Company and an update on its clinical development programs, including its two targeted cancer agents VQD-001, currently in Phase I/IIa clinical trials for solid tumors, and VQD-002 currently in clinical trials for leukemia and solid tumors. Additionally, Mr. Greenleaf will discuss the upcoming NDA filing for leishmaniasis for VQD-001. Mr. Greenleaf will also discuss the possible sale of the Company's subsidiary, Chiral Quest.
Additional information regarding the conference can be found at http://www.sachsforum.com/boston07.html.
About VioQuest Pharmaceuticals
VioQuest Pharmaceuticals, Inc. http://www.vioquestpharm.com focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in Phase I/IIa clinic trials: VQD-002 which inhibits phosphorylation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic tumors; and VQD-001, an inhibitor of specific protein tyrosine phosphatases, which has shown compelling preclinical activity in both renal and melanoma cancers. In addition, VioQuest and the U.S. Army are planning to submit an NDA to the FDA in 2007 for VQD-001 for the treatment of leishmaniasis. VioQuest's subsidiary Chiral Quest, Inc., a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug. VioQuest is seeking strategic alternatives for Chiral Quest, which may include its sale.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division, or that the FDA will approve VioQuest's planned NDA submission relating to VQD-001 for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize VQD-001 for the treatment of leishmaniasis or any other indication. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including VQD-001 and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2005. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Contact information: Daniel Greenleaf President and Chief Executive Officer 908-766-4400 ext. 115 dan.greenleaf@vioquestpharm.com Brian Lenz Chief Financial Officer 908-766-4400 ext. 117 brian.lenz@vioquestpharm.com Diane Perry VP, Investor Relations & Corporate Communications 917-834-7526 or 908-766-4400 ext. 116 diane.perry@vioquestpharm.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGOPRN Photo Desk, photodesk@prnewswire.comVioQuest Pharmaceuticals, Inc.CONTACT: Daniel Greenleaf, President and Chief Executive Officer,+1-908-766-4400 ext. 115, dan.greenleaf@vioquestpharm.com, or Brian Lenz,Chief Financial Officer, +1-908-766-4400 ext. 117,brian.lenz@vioquestpharm.com, or Diane Perry, VP, Investor Relations &Corporate Communications, +1-917-834-7526 or +1-908-766-4400 ext. 116,diane.perry@vioquestpharm.com, all of VioQuest Pharmaceuticals
